Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors

November 13, 2026 updated by: Regeneron Pharmaceuticals

A Phase 1/2 Study of REGN13089-M404-M2980, a MET-targeting Antibody-Drug Conjugate in Adult Participants With Previously Treated Advanced Solid Tumors

This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).

The study is focused on advanced cancers that have more of a protein called mesenchymal epithelial transition factor (MET) on the surface of their cells than usual. The study drug works by binding to MET on tumor cells and delivering chemotherapy directly into those cells. This may stop growth of the cancer cells and kill only the cancer cells and not the other normal tissues in your body. However, some of the chemotherapy may still affect the normal cells and side effects can still occur.

The study is looking at:

  • What side effects the study drug might cause
  • How well the study drug works
  • How much of the study drug is in the blood at different times
  • If the body reacts to the study drug, in a way that may cause the study drug to not work as well
  • What is the best dose of the study drug for treating previously treated, advanced solid tumors

Study Overview

Status

Recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

320

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • North Carolina
      • Huntersville, North Carolina, United States, 28078
        • Recruiting
        • Carolina BioOncology Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Key Inclusion Criteria:

  1. Histologically confirmed cancer (non-small cell lung cancer (epidermal growth factor receptor mutant type or epidermal growth factor receptor mutant type), colorectal cancer, gastric/gastroesophageal junction cancer, uveal melanoma, papillary renal cell carcinoma, or clear cell renal cell carcinoma) that is at an advanced stage as described in the protocol
  2. Participants must not be candidates for curative surgery or radiation
  3. Participants are required to have exhausted all therapeutic options that are expected to provide meaningful clinical benefit, either through disease relapse, treatment refractory disease, or intolerance of the therapy as described in the protocol
  4. Willing to provide tumor tissue; archival or fresh tumor tissue will be accepted as described in the protocol
  5. At least 1 lesion that is measurable by RECIST 1.1. Tumor lesions in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions after radiation
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  7. Adequate organ and bone marrow function as described in the protocol

Key Exclusion Criteria:

  1. Has received treatment with an approved systemic therapy or has participated in any study of an investigational agent or investigational device as described in the protocol
  2. Has received radiation therapy within the 28 days prior to first administration of study intervention. Palliative stereotactic radiation therapy without a thoracic or abdominal field is allowed with a washout period of 14 days from first administration of study intervention.
  3. Has undergone major surgery within the 14 days prior to first administration of study intervention
  4. Has not yet recovered (ie, grade ≤1 or baseline) from any acute toxicities resulting from prior therapy as described in the protocol
  5. Has a history of interstitial lung disease (eg, idiopathic pulmonary fibrosis, etc) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management or has imaging consistent with these diseases during the screening period. A history of radiation pneumonitis is permitted as long as pneumonitis resolved ≥6 months prior to enrollment.
  6. Has received prior treatment with an antibody-drug conjugate (ADC) that includes a topoisomerase payload
  7. Known active or untreated brain metastases or spinal cord compression. Participants are eligible if central nervous system (CNS) metastases are adequately treated, and participants have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment.

Note: Other protocol defined inclusion/ exclusion criteria apply

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Part 1: Dose Escalation

Administered per the protocol

Experimental: Part 2: Dose Expansion

Administered per the protocol

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Occurrence of dose-limiting toxicities (DLTs)
Time Frame: Up to 21 days

Part 1 (Dose Escalation)

Up to 21 days
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Time Frame: Up to approximately 5 years

Part 1 (Dose Escalation)

Up to approximately 5 years
Occurrence of Serious Adverse Events (SAEs)
Time Frame: Up to approximately 5 years

Part 1 (Dose Escalation)

Up to approximately 5 years
Occurrence of adverse event of special interests (AESIs)
Time Frame: Up to approximately 5 years

Part 1 (Dose Escalation)

Up to approximately 5 years
Objective response (OR) (investigator assessed) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
Time Frame: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective response (investigator assessed) per RECIST 1.1
Time Frame: Up to approximately 5 years

Part 1 (Dose Escalation)

Up to approximately 5 years
Concentrations of ADC
Time Frame: Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Concentrations of total antibody
Time Frame: Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Concentrations of payload (ProDXd and DXd)
Time Frame: Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Occurrence of Anti-Drug Antibodies (ADA) against REGN13089-M404-M2980
Time Frame: Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Magnitude of ADA against REGN13089-M404-M2980
Time Frame: Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Duration of response per RECIST 1.1
Time Frame: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Time to response per RECIST 1.1
Time Frame: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Progression-free survival per RECIST 1.1
Time Frame: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Overall survival
Time Frame: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Occurrence of TEAEs considered clinically significant
Time Frame: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Laboratory abnormalities considered clinically significant
Time Frame: Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Clinical Trial Management, Regeneron Pharmaceuticals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 28, 2026

Primary Completion (Estimated)

March 10, 2031

Study Completion (Estimated)

March 10, 2031

Study Registration Dates

First Submitted

October 2, 2026

First Submitted That Met QC Criteria

October 2, 2026

First Posted (Actual)

October 7, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • R13089-ONC-25128

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

IPD Sharing Time Frame

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

IPD Sharing Access Criteria

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe